Q1 sales in line with our estimates, adj. EBITDA 4% below Expect cons '23e adj.
Bonesupports första kvartal kom in över våra förväntningar och tillväxtutsikterna ser starka ut.
Karolinska Development presenterar flera intressanta datapunkter för centrala portföljbolag under Q1...
CapMan’s Q1 results were quite weak on paper, but the operational performance remained at a rather g...
Raute’s Q1 was mostly better than we estimated. Large orders have on the one hand improved outlook, ...
Q1 profitability came in soft. While growth is expected going forward, the extent of profitability r...
Redeye comments on the new financing solution that adds SEK23.
Redeye returns with a more detailed take on Episurf Medicals’ Q1 report, and we make some changes to...
Redeye provides an update following Netmore's Q1 2023 report, highlighting the company's record-brea...
Redeye updates its estimates and valuation on the back of the Q1 2023 report, where ARR and recurrin...
Redeye notes that Doro's Q1 2023 performance was somewhat weaker than anticipated, but there are ind...
Rovio's Q1 was merely a formality after the recent recommended cash offer of EUR 9.
Redeye raises its Base Case and forecasts slightly following the Q1 report.
36% org growth, 21% adj. EBIT beat on strong AM sales 27% adj.
19% CAGR in adjusted EPS for 2022-'25e Q1e: 14% NII growth q-o-q and another strong quarter on MVA C...
Q1 report due on Thursday, 4 May We lower '23e sales by ~4% as we trim Circular Energy sales The sha...
AcuCort publicerade den 28 april bolagets delårsrapport för det första kvartalet år 2023.
ARR of SEK 14.3m, up 52% y-o-y in Q1'23 Costs kept up with revenue growth We trim '23e EBITDA to SEK...
Intellego Technologies utvecklar och kommersialiserar färgindikatorer som visualiserar, kvalitetssäk...
Redeye thinks today's proposal from FCC is indeed an important step to boost customer launches in th...
